Skip to main content
Anixa Biosciences Inc logo

Anixa Biosciences Inc — Investor Relations & Filings

Ticker · ANIX ISIN · US45069V2034 LEI · 549300PW2C2QTAJL2D19 US Professional, scientific and technical activities
Open in API
Filings indexed 958 across all filing types
Latest filing 2005-09-09 Interim / Quarterly Rep…
Country US United States of America
Listing US ANIX

About Anixa Biosciences Inc

https://www.anixa.com/

Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.

Recent filings

Filing Released Lang Actions
COPYTELE, INC. 10-Q
Interim / Quarterly Report
2005-09-09 English
COPYTELE, INC.
Interim / Quarterly Report
2005-06-09 English
Regulatory Filings 2005
Regulatory Filings
2005-05-02 English
COPYTELE, INC. 10-K/A
Annual Report
2005-04-22 English
Regulatory Filings 2005
Regulatory Filings Classification · 95% confidence The document is a letter from CopyTele, Inc. to the SEC referencing comments from the SEC staff regarding the company's previously filed Form 10-K for the fiscal year ended October 31, 2004, a Form 10-K/A amendment, and a Form 10-Q for the quarterly period ended January 31, 2005. The letter discusses the effectiveness of the company's disclosure controls and procedures, material weaknesses in internal control, and responses to SEC comments. It is primarily a regulatory response letter addressing SEC staff comments on prior filings rather than the filings themselves. The document does not contain actual financial statements or substantive financial data but is a certification and explanatory letter related to prior filings. Therefore, it fits the criteria for a Regulatory Filing (RNS) rather than an Annual Report (10-K) or an Interim Report (10-Q).
2005-04-15 English
Regulatory Filings 2005
Regulatory Filings Classification · 95% confidence The document is a letter from the SEC staff to a company's CFO regarding review comments on the company's previously filed Form 10-K, 10-K/A, and 10-Q filings. It discusses the effectiveness of disclosure controls and procedures, material weaknesses identified by auditors, and requests clarifications and supplemental information. The document does not contain actual financial statements or substantive financial data but is a regulatory review comment letter related to filings. It is not the annual report (10-K) itself, nor an earnings release or other financial report. It fits the category of Regulatory Filings (RNS) as it is a compliance and review communication from the SEC staff.
2005-04-01 English

Browse filings by year

32 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.